Clinical Trial Update: Capecitabine-based Chemoradiotherapy in Combination With the IL-1 Receptor Antagonist Anakinra for Rectal Cancer Patients [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating capecitabine-based chemoradiotherapy with the IL-1 receptor antagonist anakinra for rectal cancer has completed. No efficacy or safety …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Anakinra (anakinra)
• Capecitabine (capecitabine)

Snippet

Sponsor: Goethe University | Conditions: Rectal Cancer | Phase 1 | Status: COMPLETED